Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugs

Kanve N. Suvilesh(Harry S. Truman Memorial Veterans' Hospital), Jussuf T. Kaifi(Unknown)

bioRxiv (Cold Spring Harbor Laboratory)

October 21, 2023

10.1101/2023.10.18.562944

Cited by 0

Related Papers

RNA cargos in extracellular vesicles derived from blood serum in pancreas associated conditions

|Scientific Reports|2020|88

PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer

|Cancers|2019|77

Angiogenesis index CD105 (endoglin)/CD31 (PECAM-1) as a predictive factor for invasion and proliferation in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.

|PubMed|2010|27

Pigs: Large Animal Preclinical Cancer Models

|World Journal of Oncology|2024|22

Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids

|Clinical Cancer Research|2024|22